Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

BUY
$9.38 - $20.29 $2,907 - $6,289
310 Added 71.43%
744 $15,000
Q3 2022

Nov 10, 2022

SELL
$9.52 - $13.48 $8,901 - $12,603
-935 Reduced 68.3%
434 $4,000
Q2 2022

Aug 15, 2022

BUY
$10.12 - $23.32 $12,295 - $28,333
1,215 Added 788.96%
1,369 $16,000
Q1 2022

May 12, 2022

BUY
$19.54 - $33.59 $3,009 - $5,172
154 New
154 $3,000
Q4 2021

Feb 14, 2022

SELL
$22.51 - $36.79 $3,106 - $5,077
-138 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$13.28 - $25.79 $1,593 - $3,094
-120 Reduced 46.51%
138 $4,000
Q2 2021

Aug 16, 2021

SELL
$10.5 - $14.19 $262 - $354
-25 Reduced 8.83%
258 $3,000
Q1 2021

May 17, 2021

SELL
$8.2 - $14.49 $5,190 - $9,172
-633 Reduced 69.1%
283 $3,000
Q4 2020

Feb 16, 2021

BUY
$6.87 - $8.88 $4,101 - $5,301
597 Added 187.15%
916 $7,000
Q3 2020

Nov 16, 2020

SELL
$7.48 - $9.54 $25,491 - $32,512
-3,408 Reduced 91.44%
319 $3,000
Q2 2020

Aug 13, 2020

BUY
$8.64 - $11.87 $32,201 - $44,239
3,727 New
3,727 $34,000

Others Institutions Holding OPNT

About OPIANT PHARMACEUTICALS, INC.


  • Ticker OPNT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,164,150
  • Description
  • Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overd...
More about OPNT
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.